Peptide education
BPC-157
Body Protection Compound 157 · PL 14736
BPC-157 is a synthetic 15-amino-acid peptide, originally carved out of a protective stomach protein, that the internet treats as a general repair drug. Tendons, ligaments, knees, muscle strains, gut problems: the claim list is long and confident. The human record behind it is three documents: a registered oral phase 1 trial with no posted results, an IV tolerability test in two people, and a small knee-injection chart review with no control group. Everything else is rodent data, review papers repeating rodent data, and marketing. People buy it as a proven recovery tool; the evidence says it is an unanswered question.
The human case for BPC-157 is an uncontrolled knee chart review, a two-person IV tolerability test, and a trial registration with no posted results. The reputation is much bigger than that.
Overview
Quick answer
BPC-157 often gets lumped together with Wolverine Blend, TB-500, and full-length thymosin beta-4, but those are different products with different evidence. Blend and thymosin material can explain why the market is confusing, but standalone BPC-157 benefits still need their own evidence.
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a protective protein in human gastric juice. In the sources here it is an investigational peptide sold around tissue repair and gut claims, not an approved drug for anything.
What do people use or discuss it for?
Mostly injuries: tendon and ligament problems, knee pain, muscle strains, wound healing, and recovery after training or procedures. A second cluster covers gut complaints, from general irritation to ulcerative-colitis language. Both clusters come from clinics, vendors, Reddit, and protocol blogs, not from human outcome trials.
What route and amount details are documented?
The documented schedules are narrow. The ClinicalTrials.gov oral record lists 1 mg Bepecin tablets: 1, 3, or 6 tablets in single-dose arms, and 3 tablets every 8 hours for two weeks in the repeated-dose arm. The IV pilot gave 10 mg then 20 mg in 250 cc saline over one hour on consecutive days to two adults. The knee review used single intra-articular injections around 4 mg in the BPC-only cases, plus a few BPC plus thymosin beta-4 combinations that should not be read as standalone BPC-157.
Does BPC-157 have strong human evidence for injury recovery?
No. The knee chart review is the strongest clinical item, and it had no control group, no blinding, phone follow-up, mixed knee diagnoses, and subjective outcomes. Eleven of 12 contacted BPC-only patients reported improvement, which is a lead worth testing, not a result you can bank on. The 2025 IV pilot measured tolerability in two people, not repair.
What is the main safety and quality issue?
FDA flags compounded BPC-157 for immunogenicity, peptide impurities, characterization problems, and thin route-specific safety data. Almost everything sold as BPC-157 is a research-use vial, compounded preparation, clinic supply, or gray-market capsule, so those concerns land on exactly the products people actually buy.
Reported practice
Commonly reported protocol
Injectable community protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
The small retrospective knee chart review reported subjective improvement after intra-articular BPC-157 in most contacted patients, but the design cannot tell us how well it works across injuries, routes, products, or rehab settings.
A 2025 pilot used one-hour IV infusions over two days in two adults and reported no measured biomarker changes or side effects. The study was far too small to answer repeated-use safety or benefit.
ClinicalTrials.gov lists oral PCO-02 / Bepecin tablet arms, including a two-week repeated-dose phase, but it has not posted the results needed for efficacy claims.
Review papers explain why repair and ulcerative-colitis claims keep showing up, but they do not provide symptom-improvement data or a human dosing schedule.
FDA's compounding safety-risk material lists BPC-157 because of immunogenicity, impurities, API characterization, and limited route-specific safety information.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| BPC-157 heals tendons, ligaments, joints, or soft tissue. | The main standalone human finding is the retrospective knee-pain chart review. It reported improvement in 11 of 12 BPC-only patients contacted after intra-articular injection, but it was uncontrolled, unblinded, based on phone follow-up, and did not use standardized function or imaging endpoints. | Musculoskeletal review literature and preclinical discussion connect BPC-157 to repair biology such as endothelial function, angiogenesis, inflammation, fibroblast activity, and tendon-related pathways. Those mechanisms explain why injured people keep paying attention to it. | Clinics, protocol blogs, Reddit threads, forums, and vendors commonly use recovery, tendon, ligament, joint, and soft-tissue language. That material shows recurring claims, while real outcomes can also be shaped by rehab, rest, local injections, expectations, other drugs, and time. | The recovery claim is worth studying, but the human evidence is still thin. The knee review is a useful clue, not a universal recovery guide. |
| BPC-157 helps gut problems or ulcerative colitis. | The BPC-specific sources include ulcerative-colitis review context and FDA PCAC material that lists ulcerative colitis as the use evaluated for BPC-157-related bulk substances. That is not an approved IBD indication or a patient treatment schedule. | The gut claim comes from BPC-157's gastric-peptide origin and preclinical cytoprotection, mucosal, inflammation, and healing models. | Online discussion often treats oral BPC-157 as a gut-healing product. These sources do not provide a reliable public regimen or human outcome evidence for that use. | A real research theme, but these sources do not back BPC-157 as an ulcerative-colitis or gut-symptom therapy. |
| BPC-157 has known safe IV or injectable dosing. | The IV pilot used 10 mg on day 1 and 20 mg on day 2 in two adults and reported short-term tolerability. That is a very narrow safety finding; it does not tell us how repeated IV cycles, subcutaneous cycles, intramuscular injections, or gray-market products perform. | Route changes matter because impurities, aggregation, sterility, endotoxin, concentration, and immune response can affect injectable safety independent of the intended peptide sequence. | Online BPC-157 discussion is often injection-centered. Exact amounts, frequency, and cycle length vary widely across informal reports. | The two-person IV pilot gives a concrete exposure example, but it is too small to answer repeated IV, subcutaneous, intramuscular, or gray-market product safety. |
| Oral BPC-157 works as a gut or recovery protocol. | ClinicalTrials.gov lists an oral PCO-02 / Bepecin phase 1 design with 1 mg tablets and a two-week repeated-dose phase, but the registry has not posted efficacy results. | Oral interest fits the gastric-peptide identity and gut-protection rationale. That route context still leaves benefit, product equivalence, and long-term safety untested. | Vendors and online users often discuss oral capsules or tablets for gut complaints. Those discussions are different from published trial results. | The oral trial gives route and amount details, not evidence that oral BPC-157 improves gut symptoms or recovery. |
| A research-use or compounded vial is equivalent to studied BPC-157. | None of the current human sources verifies that public vials, compounded products, clinic supply, or vendor products match the studied material. | This is an identity and manufacturing question: sequence, purity, impurities, aggregation, concentration, sterility, endotoxin, diluent, storage, and chain of custody all matter. | Gray-market listings often lean on purity percentages, COA language, and recovery claims. Those clues do not replace regulated product controls. | A shared molecule name is not the same as having the studied product. Route-specific evidence has to cover identity, concentration, sterility, endotoxin, impurities, and handling. |
| BPC-157 plus TB-500 evidence carries over to standalone BPC-157. | The knee chart review included BPC-only patients and a few BPC plus thymosin beta-4 cases. The mixed cases are useful context, but they are not evidence for one combined claim about BPC-157, TB-500 fragments, or Wolverine-style combinations. | BPC-157 and thymosin-related products have different identities and evidence histories. Blending names can create a stronger-sounding repair claim than the human data support. | Forums, vendors, and protocol blogs often stack BPC-157 with TB-500 or call the combination Wolverine Blend. That shows how it is marketed, not that BPC-157 alone has the same effect. | TB-500 and blend claims are separate from standalone BPC-157 evidence. |
Bottom line
Main takeaway
BPC-157 is sold as a repair shortcut, but no human trial has shown it heals anything. The supporting material is three early documents plus a lot of animal data and marketing.
Judge each claim by route and product. The oral registry, the two-person IV pilot, and the uncontrolled knee review each cover one narrow exposure, and none of them verifies the injectable vials most people use.
The core record is NCT02637284, the 2025 two-person IV pilot, the 2021 knee chart review, two narrative reviews, and FDA compounding material. TB-500 and blend data belong to different pages and should not be folded in.
Identity
What it is
BPC-157, also called Body Protection Compound 157, PL 14736, or Bepecin in trial materials, is a 15-amino-acid synthetic peptide with the sequence GEPPPGKPADDAGLV. It was derived from a protective protein in gastric juice, which is the origin of both the gut claims and the oral-stability argument.
The repair reputation comes from a large rodent and cell literature: tendon outgrowth, angiogenesis, nitric-oxide signaling, fibroblast activity, gut protection, even counteracting NSAID damage in animals. That literature is why researchers keep proposing human studies. It is also most of what sellers cite.
The human side never arrived. A phase 1 oral trial was registered and never posted results. An IV pilot dosed two people for two days and measured tolerability. One clinic retrospectively phoned knee-pain patients it had injected, and most said they felt better. That is the entire standalone human record.
Meanwhile the market sells it as a finished answer: vials, capsules, clinic injections, and stacks with TB-500 under names like Wolverine Blend. The gap between those two paragraphs is the whole story of this compound.
How people talk about it online
After FDA's safety-risk attention, some compounding channels rebranded the same molecule as PDA (pentadecapeptide arginate), a slightly different salt form with the same peptide chain. A name change on a label does not change what is in the vial, and the identity question stays the same either way.
Reddit threads, forums, clinic pages, and protocol blogs talk about BPC-157 for nagging tendon and ligament problems, knee pain, muscle strains, wound healing, and gut symptoms. A recurring convention is injecting subcutaneously near the injury, typically described at 250 to 500 mcg once or twice daily for 4 to 8 weeks. That convention is community folklore, not a tested protocol, and no human study establishes any dose.
Oral products get discussed for gut claims at roughly 500 mcg to 1 mg daily, leaning on the gastric-protein origin story. Human oral outcome data do not exist, and capsule identity is unverified.
A large share of the conversation is actually about stacks: BPC-157 plus TB-500, often sold as Wolverine Blend. Stack talk borrows credibility from both names at once, which makes standalone BPC-157 sound more established than its three-document human record warrants.
Use context
Routes, doses, and cycle patterns
The route and amount details come from a few narrow places: an oral ClinicalTrials.gov record, a two-day IV pilot, and a small intra-articular knee-pain chart review. Clinic, vendor, Reddit, forum, and protocol-blog patterns show the goals people bring to BPC-157, but they have not produced a reliable cycle for general recovery or gut use.
Human studies and product labels
Oral PCO-02 / Bepecin phase 1 registration
- Purpose
- Early safety and pharmacokinetic development
- Context
- ClinicalTrials.gov record
- Route
- Oral tablets
- Amount
- Phase 1a listed 1, 3, or 6 tablets, each containing 1 mg of Bepecin; phase 1b listed 3 tablets per dose
- Frequency
- Phase 1b listed every 8 hours
- Duration
- Phase 1b listed two weeks
The oral phase 1 registry is the most concrete oral schedule found for standalone BPC-157. It is a registered early-phase study design, not a benefit result or evidence for routine gut use.
Intravenous BPC-157 pilot
- Purpose
- Short-term tolerability
- Context
- Two-person human pilot study
- Route
- Intravenous infusion
- Amount
- 10 mg in 250 cc saline on day 1; 20 mg in 250 cc saline on day 2
- Frequency
- Once daily for two study days
- Duration
- Two days, with blood work and vital signs checked around the infusions
The pilot reported no measured effects on tested biomarkers and no reported side effects in two adults. It is too small for longer IV use or any recovery outcome.
Intra-articular knee-pain chart review
- Purpose
- Knee-pain symptom reporting
- Context
- Retrospective clinic chart review
- Route
- Intra-articular knee injection
- Amount
- BPC-only cases are summarized around 4 mg; several combined cases used BPC plus thymosin beta-4 amounts
- Frequency
- Single injection in the reported review
- Duration
- Follow-up varied, with many injections occurring 6 months to 1 year before the survey
The review reported subjective improvement in most contacted patients, but it was uncontrolled, unblinded, and mixed BPC-only with a few BPC plus thymosin beta-4 cases.
FDA PCAC BPC-157-related bulk-substance review
- Purpose
- Ulcerative-colitis nominated-use context
- Context
- FDA advisory committee review
- Route
- Regulatory review context, not use guidance
- Amount
- FDA review does not provide a usable amount
- Frequency
- FDA review does not provide a usable schedule
- Duration
- FDA review does not provide a usable course length
PCAC voted on July 23, 2026 to recommend BPC-157 free base and BPC-157 acetate for the 503A Bulks List (8-6, one abstention), with ulcerative colitis as the use evaluated. The recommendation is non-binding; FDA rulemaking follows, so this remains regulatory review context, not approval or dosing guidance.
Real-world discussion
Injectable community protocols
- Purpose
- Tendon, muscle, and injury-recovery discussion
- Context
- Forums, clinics, and protocol blogs
- Route
- Subcutaneous injection, often described near the injury area in community lore
- Amount
- Community protocols commonly describe 250 to 500 mcg per injection, once or twice daily.
- Frequency
- Once or twice daily in most community descriptions
- Duration
- Most often 4 to 8 week runs, sometimes extended to 12 weeks
These are the ranges community sources converge on, but no human study establishes a BPC-157 dose, and the inject-near-the-injury convention is mechanistic folklore rather than tested practice. Informational context, not advice.
Oral community protocols for gut claims
- Purpose
- Gut and digestive discussion
- Context
- Capsule products, forums, and clinic pages
- Route
- Oral capsules or oral solutions
- Amount
- Community protocols commonly describe 500 mcg to 1 mg per day
- Frequency
- Once or twice daily
- Duration
- Most often 4 to 8 week runs
Oral discussion leans on BPC-157's origin as a gastric pentadecapeptide and on preclinical gut data; human oral outcome data do not exist. Product identity in capsules is unverified. Informational context, not advice.
What varies
- How to read the sources: a trial registry can give route and schedule context, a knee chart review can show one clinic's symptom follow-up, Reddit can capture user goals, and vendor pages mostly show how the product is being sold.
- Route: oral tablets, IV infusion, intra-articular knee injection, subcutaneous or intramuscular market use, and oral capsules have different absorption and safety problems.
- Amount: a 1 mg oral tablet, a two-day IV pilot amount, and an injection-market cycle are not the same exposure.
- Frequency and duration: the only clean repeated schedule here is the oral phase 1b registry pattern; informal cycles vary too much to treat as one standard.
- Product: sequence, salt form, impurity profile, aggregation, sterility, endotoxin, concentration, diluent, storage, and chain of custody change what someone is actually handling.
Human data
Human evidence
Three sources carry the entire human case. Before all of them, the Croatian group ran phase 1 and phase 2 ulcerative-colitis programs using rectal BPC-157 enemas up to 80 mg, reporting tolerability in phase 1 and a positive signal in phase 2, with only abstracts ever published. Notably, orally or rectally administered BPC-157 was not detected in blood in that work, which supports a gut-local action and leaves the systemic repair story unanswered. After those, the oral phase 1 registry entry documents a tablet schedule but no posted efficacy results. The 2025 IV pilot shows two adults tolerated single-day infusions of 10 and 20 mg, which says nothing about repeated use or repair. The 2021 knee-pain chart review reported subjective improvement in 11 of 12 contacted BPC-only patients, with no control group, no blinding, and mixed diagnoses. Review articles explain the mechanism rationale; they add no patients. No controlled human outcome trial exists for any marketed use.
Evidence maturity
BPC-157's evidence chain stops at small early human reports; the market runs far ahead of the data.
Robust rodent and cell literature across tendon, gut, and wound models.
Oral phase 1 registry entry without posted results, a two-person IV pilot, and an uncontrolled knee chart review.
None posted for any marketed claim.
Gray-market vials, FDA safety-risk listing, and a non-binding 2026 PCAC vote to recommend 503A listing.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| PCO-02 / Bepecin oral phase 1 record | Healthy volunteers in an early-phase registered study | ClinicalTrials.gov phase 1 registration | Oral BPC-157 / Bepecin development context | The registry lists oral tablet schedules, including 1 mg tablets and a two-week repeated-dose phase. | The registry has not posted efficacy results, so the oral development details only supply context for recovery or gut-treatment claims. | weak |
| IV BPC-157 pilot | Two adults in a private-clinic pilot | Two-person pilot study | Intravenous BPC-157 tolerability context | The pilot reported no measurable changes in tested biomarkers and no reported side effects after 10 mg IV on day 1 and 20 mg IV on day 2. | Very small, short, not randomized, not blinded, and not designed to test injury repair, gut symptoms, or repeated-cycle safety. | limited human tolerability finding |
| Intra-articular BPC-157 knee-pain chart review | Sixteen contacted knee-pain patients from a clinic chart review | Retrospective chart review with phone follow-up | Intra-articular BPC-157, with several BPC plus thymosin beta-4 cases | The abstract reported significant improvement in 11 of 12 BPC-only patients and 3 of 4 BPC plus thymosin beta-4 patients. | No control group, no blinding, no standardized functional tool, variable follow-up, mixed knee conditions, and some combined-peptide exposure. | weak human finding |
| Musculoskeletal BPC-157 narrative review | Musculoskeletal-healing literature context | Narrative review | BPC-157 repair-claim context | The review helps map repair mechanisms and musculoskeletal claims around BPC-157. | A narrative review cannot define a patient-level regimen or support broad tendon, ligament, muscle, or joint recovery claims. | weak |
| Ulcerative-colitis BPC-157 review context | Ulcerative-colitis claim context | Review-level source | BPC-157 gut-claim context | The source supports why BPC-157 appears in gut and ulcerative-colitis discussions. | It gives background for the gut claim, but not an approved use, a reliable regimen, or controlled human outcome evidence for gut symptoms. | weak |
Cautions
Safety and unknowns
- No LD50 has been established for BPC-157 even at roughly a thousand times typical amounts in animal work. That sounds reassuring until you realize a lethal-dose figure is required for any approved drug, so the same clean animal profile that markets the compound is also one of the gaps blocking a human program.
- The available BPC-specific human sources are too small or indirect to answer long-term safety, repeated-cycle safety, or rare adverse-event risk.
- Route-specific safety depends on the route. Oral tablets, IV infusion, intra-articular injection, subcutaneous injection, intramuscular injection, and topical or local market use do not carry the same risk profile.
- FDA lists compounded BPC-157 as a safety-risk concern because of potential immunogenicity, peptide-related impurities, API characterization complexity, and limited safety information for proposed routes.
- Product identity and sterility are practical safety issues for any injected peptide. For BPC-157, the practical risk is often the vial itself: whether the listed peptide is present at the stated concentration, whether endotoxin and sterility were controlled, whether the material survived storage, and whether the test document can be tied to that exact lot.
- The knee-pain chart review relied on subjective follow-up and mixed exposure in a small clinic population, so it cannot rule out harms or show benefit across other injuries.
- Mechanisms involving angiogenesis, nitric-oxide signaling, inflammation, and tissue remodeling are biologically active themes. The current human sources do not settle whether those pathways create long-term off-target concerns in broad real-world use.
Product quality
A vial label is only a starting point
BPC-157 is often encountered as compounded supply, research-use vials, oral capsules, clinic inventory, or gray-market product listings rather than as an approved finished drug.
FDA's BPC-157 concern is partly a manufacturing and characterization concern: peptide-related impurities, aggregation, API identity, route, and limited safety information can change the risk.
A name on a vial does not settle product quality. A paper can discuss BPC-157 biology without showing that a marketed product is authentic, sterile, potent, stable, or suitable for injection.
Identity
The label has to match the peptide sequence and salt form, not just a marketing name.
Impurities and aggregation
Peptide-related impurities and aggregates can affect immune response and tolerability, especially for injectable products.
Sterility and endotoxin
Injection-centered use raises sterility, endotoxin, concentration, and tissue-irritation risks that oral or literature-only discussions cannot resolve.
Concentration and vial math
A milligram claim is only meaningful if assay, fill, reconstitution, and storage are documented for that lot.
Chain of custody
Vendor-posted test summaries may show a claimed batch result, but regulated manufacturing, handling, and release controls still need separate documentation.
Mechanism
How it is proposed to work
BPC-157 is discussed as a repair and gut peptide because preclinical and review literature connect it to tissue-healing biology: blood-vessel and endothelial signaling, nitric-oxide pathways, inflammation, fibroblast and tendon behavior, and gastrointestinal protection. That biology explains why studies are worth doing, but it does not show that an available product heals a human tendon, ligament, wound, joint, or gut condition.
Musculoskeletal claims usually point to angiogenesis, endothelial function, fibroblast activity, tendon outgrowth, cell survival, and migration themes described in review and preclinical literature.
Gut claims usually point to gastric-peptide identity, cytoprotection, mucosal injury models, inflammation, and ulcerative-colitis review context.
Nitric-oxide and vascular-signaling claims are biologically important because they could affect repair and blood-flow responses, but the same broad biology is why long-term and route-specific safety still matters.
The mechanism gives BPC-157 a reason to be studied for repair. The human outcome record is still limited to the oral registry, IV pilot, and knee chart review.
BPC-157 is a 15-amino-acid fragment derived from a human gastric-juice protein, which is the basis of the oral-stability rationale. Proposed pathways in the preclinical literature include nitric-oxide-system interaction, VEGF-linked angiogenesis, growth-hormone-receptor expression in tendon fibroblasts, and FAK-paxillin signaling tied to cell migration.
A recurring theme in the animal literature is counteraction of NSAID and corticosteroid toxicity, which is one reason the compound is discussed alongside conventional injury care rather than only as a standalone agent.
Structure
Structure and sequence
A proline-rich pentadecapeptide. Four proline residues are the sequence feature most often cited when discussing conformational rigidity and unusual stability.
A 15-residue chain of 15 amino acids. Select any atom in the model to inspect its element, residue, and structural role.
FAQ
Common questions
Does BPC-157 work for tendon or injury recovery?
Not established in people. The standalone human record is an oral phase 1 registry entry without posted results, a two-person IV tolerability pilot, and an uncontrolled retrospective knee-pain chart review. The strong repair data are in rodents, which makes the claim worth studying but not yet dependable.
What doses do people report using?
Community protocols commonly describe 250 to 500 mcg by subcutaneous injection once or twice daily for 4 to 8 weeks, and 500 mcg to 1 mg daily in oral products aimed at gut claims. No human study establishes any dose, so these are community conventions, not verified regimens.
Is BPC-157 legal?
It is not FDA-approved for any use. On July 23, 2026, the Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend BPC-157 bulk substances for the 503A Bulks List; the recommendation is non-binding and compounding status is unchanged while FDA rulemaking proceeds. Research-use vials are sold in a gray market where a for-research-only label does not make human use legal or the product verified.
Is BPC-157 the same as TB-500 or the Wolverine blend?
No. BPC-157 is a specific 15-amino-acid peptide. TB-500 is a thymosin beta-4 fragment product, and Wolverine-style blends combine the two. They carry different evidence and identity questions that blend marketing often blurs.
Details
Technical details
Sources
References
- 1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 3.
PubMed. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing 2025.
PMID:40789979 Accessed 2026-06-08.
Narrative review that helps explain the recovery discussion but does not prove broad clinical recovery efficacy.
- 4.
ClinicalTrials.gov. ClinicalTrials.gov record NCT02637284 2015.
NCT02637284 Accessed 2026-06-08.
Trial record tracked for BPC-157 evidence mapping; no posted results were used for efficacy conclusions.
- 5.
PubMed. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157 2012.
PMID:22300085 Accessed 2026-06-08.
Ulcerative-colitis review context; does not provide a practical regimen.
- 6.
PubMed. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study 2025.
PMID:40131143 Accessed 2026-06-15.
Two-person IV tolerability pilot; reports safety observations without testing efficacy or establishing a practical regimen.
- 7.
PubMed. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain 2021.
PMID:34324435 Accessed 2026-06-15.
Small retrospective knee-pain chart review; useful human context, but too limited to generalize into a protocol.